The current place of aprotinin in the management of bleeding

Anaesthesia

Volumn 70, Issue S1, 2015, Pages

  Royston, D ^a  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; HEMOSTATIC AGENT; TRANEXAMIC ACID;

ANIMAL; HEMORRHAGE; HUMAN;

ANIMALS; APROTININ; HEMORRHAGE; HEMOSTATICS; HUMANS; TRANEXAMIC ACID;

EID: 84925225807     PISSN: 00032409     EISSN: 13652044     Source Type: Journal    
DOI: 10.1111/ANAE.12907     Document Type: Review

References (22)

1. Weitz JI, Leslie B, Hirsh J, Klement P. Alpha 2-antiplasmin sup-plementation inhibits tissue plasminogen activator-induced fi-brinogenolysis and bleeding with little effect on thrombolysis. Journal of Clinical Investigation 1993; 91: 1343–50.
2. de-Bono DP, Pringle S, Underwood I. Differential effects of ap-rotinin and tranexamic acid on cerebral bleeding and cutane-ous bleeding time during rt-PA infusion. Thrombosis Research 1991; 61: 159–63.
3. Garabedian HD, Gold HK, Leinbach RC, et al. Bleeding time prolongation and bleeding during infusion of recombinant tissue-type plasminogen activator in dogs: potentiation by aspirin and reversal with aprotinin. Journal of the American College of Cardiology 1991; 17: 1213–22.
4. Fears R, Greenwood J, Hearn J, Howard BS, Morrow G, Standring R. Inhibition of the fibrinolytic and fibrinogenolytic activity of plasminogen activators in vitro by the antidotes ε-aminocaproic acid, tranexamic acid and aprotinin. Fibrinolysis 1992; 6: 79–86.
5. Royston D. Aprotinin versus lysine analogues: the debate con-tinues. Annals of Thoracic Surgery 1998; 65(4 Suppl): S9–19.
6. Samama CM, Langeron O, Rosencher N, et al. Aprotinin versus placebo in major orthopedic surgery: a randomized, double-blinded, dose-ranging study. Anesthesia and Analgesia 2002; 95: 287–93.
7. Porte RJ, Molenaar IQ, Begliomini B, et al. Aprotinin and transfusion requirements in orthotopic liver transplantation: a mul-ticentre randomised double-blind study. EMSALT Study Group. Lancet 2000; 355: 1303–9.
8. McIlroy DR, Myles PS, Phillips LE, Smith JA. Antifibrinolytics in cardiac surgical patients receiving aspirin: a systematic review and meta-analysis. British Journal of Anaesthesia 2009; 102: 168–78.
9. Lindvall G, Sartipy U, van der Linden J. Aprotinin reduces bleeding and blood product use in patients treated with clopi-dogrel before coronary artery bypass grafting. Annals of Thoracic Surgery 2005; 80: 922–7.
10. van der Linden J, Lindvall G, Sartipy U. Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: a double-blind, placebo-controlled, randomized clinical trial. Circulation 2005; 112(9 Suppl): I276–80.
11. Bittner HB, Lehmann S, Rastan A, Mohr FW. Impact of clopido-grel on bleeding complications and survival in off-pump coronary artery bypass grafting. Interactive Cardiovascular and Thoracic Surgery 2012; 14: 273–7.
12. Mangano DT, Tudor IC, Dietzel C. The risk associated with ap-rotinin in cardiac surgery. New England Journal of Medicine 2006; 354: 353–65.
13. Schneeweiss S, Seeger JD, Landon J, Walker AM. Aprotinin during coronary artery bypass grafting and risk of death. New England Journal of Medicine 2008; 358: 771–83.
14. Shaw AD, Stafford-Smith M, White WD, et al. The effect of ap-rotinin on outcome after coronary-artery bypass grafting. New England Journal of Medicine 2008; 358: 784–93.
15. Ott E, Mazer CD, Tudor IC, et al. Coronary artery bypass graft surgery–care globalization: the impact of national care on fatal and nonfatal outcome. Journal of Thoracic and Cardiovascular Surgery 2007; 133: 1242–51.
16. Fergusson DA, Hebert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. New England Journal of Medicine 2008; 358: 2319–31.
17. http://www.hc-sc.gc.ca/dhp-mps/medeff/advise-consult/eap-g ce:trasylol/final_rep-rap-eng.php (accessed 30/08/2014).
18. Dietrich W, Ebell A, Busley R, Boulesteix AL. Aprotinin and anaphylaxis: analysis of 12,403 exposures to aprotinin in cardiac surgery. Annals of Thoracic Surgery 2007; 84: 1144–50.
19. Scheule AM, Jurmann MJ, Wendel HP, Haberle L, Eckstein FS, Ziemer G. Anaphylactic shock after aprotinin reexposure: time course of aprotinin-specific antibodies. Annals of Thoracic Surgery 1997; 63: 242–4.
20. Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Tait G, Beattie WS. The risk-benefit profile of aprotinin versus tra-nexamic acid in cardiac surgery. Anesthesia and Analgesia 2010; 110: 21–9.
21. Sander M, Spies CD, Martiny V, Rosenthal C, Wernecke KD, von Heymann C. Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. Critical Care 2010; 14: R148.
22. Walkden GJ, Verheyden V, Goudie R, Murphy GJ. Increased perioperative mortality following aprotinin withdrawal: a real-world analysis of blood management strategies in adult cardiac surgery. Intensive Care Medicine 2013; 39: 1808–17.